Status:
UNKNOWN
Embryos With Preimplantation Genetic Testing for Aneuploidies (PGT-A) Inconclusive Result: Clinical Implications
Lead Sponsor:
IVI Vigo
Collaborating Sponsors:
Instituto Valenciano de Infertilidad, IVI VALENCIA
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Conditions:
Embryo Disorder
Eligibility:
FEMALE
18-45 years
Brief Summary
One of the most remarkable improvements in trophoectoderm cells biopsy is the robustness of diagnosis as result of analyzing multiple cells. However, there is a proportion of embryos that lack of diag...
Detailed Description
The main objective of assisted reproduction technologies (ART) is to achieve a healthy live newborn. The selection of an euploid embryo using PGT-A, offers theoretical advantages including increased i...
Eligibility Criteria
Inclusion
- Cycles of embryo transfer from patients with at least one euploid embryo (no rebiopsy group):
- Women age 18-45 years.
- PGT-A Indication.
- All embryos with informative results.
- Women age 18-45 years.
- PGT-A Indication.
- At least one embryo result with lack of diagnosis.
- At least one rebiopsied embryo.
- At least one euploid result from rebiopsied embryo.
- Single embryo transfer.
Exclusion
- Double embryo transfer
Key Trial Info
Start Date :
February 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 25 2022
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04734769
Start Date
February 20 2021
End Date
November 25 2022
Last Update
February 2 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.